Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 219

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

miR-221 Silencing Blocks Hepatocellular Carcinoma and Promotes Survival

Open access
Park, Jong-Kook, Kogure, Takayuki, Nuovo, Gerard J., Jiang, Jinmai, He, Lei, Kim, Ji Hye, Phelps, Mitch A., Papenfuss, Tracey L., Croce, Carlo M., Patel, Tushar, Schmittgen, Thomas D.·2011·Cancer Research

Abstract

Patients with advanced hepatocellular carcinoma (HCC) face a dismal prognosis because of a lack of any effective therapies. To address this situation, we conducted a preclinical investigation of the therapeutic efficacy of oligonucleotides directed against the oncogenic microRNA miR-221, which has been implicated in HCC. Of 9 chemistries evaluated, we determined that a 2′-O-methyl phosphorothioate-modified anti-miR-221 oligonucleotide was most effective at reducing proliferation in vitro. A cholesterol-modified isoform of anti-miR-221 (chol-anti-miR-221) exhibited improved pharmacokinetics and liver tissue distribution compared with unmodified oligonucleotide. Chol-anti-miR-221 significantly reduced miR-221 levels in liver within a week of intravenous administration and in situ hybridization studies confirmed accumulation of the oligonucleotide in tumor cells in vivo. Within the same period, chol-anti-miR-221 reduced tumor cell proliferation and increased markers of apoptosis and cell-cycle arrest, elevating the tumor doubling time and increasing mouse survival. Taken together, our findings offer a preclinical proof of efficacy for chol-anti-miR-221 in a valid orthotopic mouse model of HCC, suggesting that this targeted agent could benefit treatment for patients with advanced HCC. Cancer Res; 71(24); 7608–16. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-11-1144

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 219

Metadata

Authors
Park, J.-K., Kogure, T., Nuovo, G. J., Jiang, J., He, L., Kim, J. H., Phelps, M. A., Papenfuss, T. L., Croce, C. M., Patel, T., & Schmittgen, T. D.
Venue
Cancer Research
Published
2011-12-15
Volume
71
Issue
24
Pages
7608-7616
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2000961142
Cited by
219
References
5
FWCI
7.95
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: miR-221 Silencing Blocks Hepatocellular Carcinoma and Promotes Survival. https://app.cochat.ai/papers/10.1158/0008-5472.can-11-1144
The paper
Park, J.-K., Kogure, T., Nuovo, G. J., Jiang, J., He, L., Kim, J. H., Phelps, M. A., Papenfuss, T. L., Croce, C. M., Patel, T., & Schmittgen, T. D. (2011). miR-221 Silencing Blocks Hepatocellular Carcinoma and Promotes Survival. Cancer Research. https://doi.org/10.1158/0008-5472.can-11-1144

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.